Fortrea (NASDAQ:FTRE – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Profitability
This table compares Fortrea and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortrea | -3.18% | 10.72% | 2.17% |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Fortrea and Champions Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortrea | 2 | 3 | 7 | 0 | 2.42 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
Fortrea currently has a consensus target price of $22.80, indicating a potential downside of 4.68%. Given Fortrea’s stronger consensus rating and higher possible upside, research analysts plainly believe Fortrea is more favorable than Champions Oncology.
Valuation & Earnings
This table compares Fortrea and Champions Oncology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fortrea | $2.72 billion | 0.84 | -$986.20 million | ($0.91) | -26.29 |
| Champions Oncology | $59.42 million | 1.12 | -$1.17 million | ($0.08) | -59.50 |
Champions Oncology has lower revenue, but higher earnings than Fortrea. Champions Oncology is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
41.3% of Champions Oncology shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 46.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Fortrea has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
Summary
Fortrea beats Champions Oncology on 7 of the 13 factors compared between the two stocks.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
